PT-141: research overview

The short version

PT-141 is the research-chemical name for bremelanotide, a synthetic cyclic heptapeptide that activates melanocortin receptors — specifically MC4R — in the hypothalamus and limbic system. Unlike blood-flow-based approaches to sexual function, it works centrally: it targets the brain circuitry that generates sexual desire and motivation ^[9][12].

The honest regulatory picture: bremelanotide was approved by the US FDA in 2019 specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women ^[12]. That approval is based on two Phase 3 randomized controlled trials involving 1,267 premenopausal women, where it met both coprimary endpoints — improved sexual desire and reduced desire-related distress ^[10]. All other uses — including use in men, in postmenopausal women, or to enhance sexual performance in people without HSDD — are off-label and not approved. Research-chemical PT-141 sold outside the pharmaceutical system is not an approved product, is for laboratory research only, and is not for human consumption. This page summarizes the evidence; it does not give advice and lists no dose for any individual.

What it is

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide — a chain of seven amino acids with a lactam bridge between two of the side chains, creating a ring structure. Its IUPAC sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It is a structural relative of Melanotan 2, with key differences: the C-terminal amide of Melanotan 2 is replaced by a carboxylic acid in bremelanotide, and the ring closure is via an Asp-Lys lactam rather than Asp-Lys in the precursor. These structural differences produce a compound that does not cause the sustained skin tanning associated with Melanotan 2, though some pigmentation effects with repeated dosing have been documented (see cautions below).

Bremelanotide is distinct from alpha-MSH, Melanotan 2, and KPV — and it acts on a different receptor profile than afamelanotide (which targets MC1R primarily for photosensitivity disorders). PT-141 is selective for MC3R and MC4R.

How it works

PT-141 (bremelanotide) targets two melanocortin receptors: MC4R and (to a lesser degree) MC3R. MC4R is expressed in hypothalamic regions including the medial preoptic area and paraventricular nucleus, and in limbic structures involved in motivation, reward, and emotional processing. Activating MC4R in these circuits is thought to engage dopaminergic pathways that drive sexual desire and motivation — the wanting of sex, rather than the physiological mechanics of sexual response ^[9].

A 2022 neuroimaging study put a mechanism to this in humans: in a randomized crossover fMRI study of 31 premenopausal women with HSDD, MC4R agonism significantly increased sexual desire for up to 24 hours and altered task-based brain activity in response to erotic stimuli — specifically enhancing amygdala-insula functional connectivity and cerebellar/supplementary-motor activity ^[9]. This is direct in-human mechanistic evidence that MC4R agonism shifts how the brain processes sexual information.

A 2025 hamster study offered an important nuance: bremelanotide did not enhance sexual reward (conditioned place preference) in female Syrian hamsters, suggesting it may not act through the same VTA-to-nucleus-accumbens reward circuit that mediates other reinforcing behaviors ^[8]. The picture of exactly which brain circuits drive its effects in humans is still being refined.

Important: PT-141 does not act on the HPG hormone axis in the way kisspeptin does, and does not directly raise testosterone or LH. It is also not a PDE-5 inhibitor — it does not act on vascular smooth muscle or improve blood flow directly. Its route to sexual function is neural, not hormonal or vascular.

What the research shows

Phase 3 trials: RECONNECT. Two identical, large, randomized double-blind placebo-controlled trials (the RECONNECT program) enrolled 1,267 premenopausal women with acquired, generalized HSDD over 24 weeks. Bremelanotide 1.75 mg subcutaneous as-needed produced statistically significant improvement in sexual desire (integrated FSFI-desire domain +0.35 vs placebo, P<.001) and significant reduction in desire-related distress (integrated FSDS-DAO item 13 -0.33, P<.001) — both coprimary endpoints met in both trials ^[10]. The most common adverse events were nausea, flushing, and headache.

Long-term safety extension. In the 52-week open-label extension of RECONNECT (684 women enrolled), no new safety signals emerged and the sexual-desire improvements were sustained. The most common drug-related treatment-emergent adverse events over the long term were nausea (40.4%), flushing (20.6%), and headache (12.0%) ^[11]. Nausea was the leading reason for discontinuation.

Neuroimaging mechanism. The 2022 fMRI crossover study in 31 premenopausal women with HSDD found that MC4R agonism enhanced amygdala-insula connectivity and cerebellar activity in response to erotic stimuli, alongside increased self-reported desire for up to 24 hours post-dose ^[9]. This gives the Phase 3 outcomes a brain-imaging mechanistic footprint.

Animal nuance. The 2025 Syrian hamster study found MC4R and MC3R mRNA in VTA dopamine neurons, but bremelanotide did not alter melanocortin-receptor mRNA expression in the mesolimbic system and did not produce a conditioned place preference for the sexual encounter — suggesting that in this model, bremelanotide activates desire without making sex additionally rewarding ^[8]. This distinction between "desire" and "reward reinforcement" is an active area of research.

Prescribing information. The approved US label specifies: one 1.75 mg subcutaneous as-needed dose, no more than one dose per 24 hours, no more than 8 doses per month; terminal half-life ~2.7 hours (range 1.9-4.0 h); volume of distribution 25.0 L; renal and fecal excretion of 64.8% and 22.8% respectively; and a contraindication in uncontrolled hypertension or known cardiovascular disease, due to a transient blood-pressure increase ^[12].

Reported effects, cautions & safety

The following anecdotal reports come from patient review platforms (drugs.com, WebMD), peptide-user forums, and telehealth-clinic blog accounts. They are anecdotal, not clinical evidence — individual experiences that vary widely and are not studied outcomes. PT-141 has unusually rich community anecdote given its approved pharmaceutical status, but research-chemical use context differs from the approved clinical setting.

Anecdotal signals: potential benefits reported

• Stronger sexual desire and "wanting." The most consistent theme: people report wanting sex again — a mental shift toward interest rather than just physical readiness. They often contrast this with blood-flow-based approaches, describing the desire as coming from the head, not the body. This is very commonly reported across review platforms and aligns with the MC4R desire-circuit mechanism ^[9].
• Greater physical arousal and sensitivity. People frequently describe feeling more physically responsive, more sensitive to touch, and arousal building on its own — sometimes waking up aroused hours after dosing. The reported feeling is often described as a return of responsiveness.
• Easier or more intense orgasm. Some users report orgasms that come more easily or feel more intense — usually described as a secondary effect accompanying the desire and arousal rise, not a guaranteed result. Variability between individuals is marked.
• Spontaneous erections (men, off-label). In the off-label male research-use community, spontaneous erections and a stronger sense of sexual interest are frequently reported. Users describe this as different from other approaches because the urge precedes the physical response. This use is not approved.
• Stronger sense of emotional closeness. Occasionally reported — some users say they feel more emotionally present and connected with a partner during intimacy. Less commonly mentioned than desire and arousal effects; not a measured outcome.
• Delayed onset, long window of effect. Frequently noted: effects often take 30 minutes to a few hours to appear and can extend into the next day. Many describe this longer window as a feature; others find the delay frustrating for planning.

Anecdotal signals: adverse effects reported

• Nausea. By far the most common complaint — reported as very commonly by users and documented in 40.4% of long-term-study participants ^[11]. Usually starts within 30 minutes and lasts a couple of hours; often worst with the first dose and easing with subsequent use. Ranges from a brief queasy wave to nausea with vomiting in some.
• Flushing and warmth. A warm flushed feeling with facial and sometimes chest reddening — frequently reported, typically within the first hour and clearing within a couple of hours. Some describe alternating hot and cold spells.
• Headache. Commonly reported; usually mild and short-lived, clearing as the compound wears off ^[11].
• Injection-site irritation. Redness, soreness, or a small bump at the injection site — common and generally minor. Rotating the injection site is a frequently mentioned approach.
• Tingling, pins-and-needles, heightened skin sensitivity. Occasionally reported — clustered with flushing and nausea shortly after dosing; generally described as passing within a few hours. A few also report brief anxiety or restlessness in this window.
• Fatigue or drowsiness. Occasionally reported; usually clearing the same day. Some dose in the evening so tiredness overlaps with sleep.
• Skin, gum, or mole darkening with frequent use. With repeated frequent dosing, some report darkening of the skin, gums, or freckles, and changes to existing moles. Tied to the compound's activity on pigment-making cells (MC1R); more prominent in people with darker skin and with higher dosing frequency. Some report the darkening did not fully reverse after stopping — which is why the approved label limits dosing frequency ^[12].
• No effect at all. A real and recurring report: some people get every side effect and no benefit to desire or arousal. Non-response is described across review sites and is a genuine individual-level outcome.

Safety cautions from the literature and the approved label:

• Approved only for premenopausal women with HSDD; all other use is off-label. Men, postmenopausal women, and use for sexual performance enhancement are outside the studied and approved indication ^[12].
• Transient blood-pressure rise; contraindicated in uncontrolled hypertension or cardiovascular disease. A short-lived increase in blood pressure is documented, with a corresponding small drop in heart rate, returning to baseline within hours. The approved label specifies this contraindication ^[12].
• Nausea can be severe and is the leading discontinuation reason. ~40% of long-term users experience it; in some it is severe enough to cause vomiting ^[11].
• Hyperpigmentation with frequent dosing. Skin and mucous-membrane darkening with repeated use is a documented and potentially irreversible effect; the label limits dosing frequency partly to manage this ^[12].
• Possible liver enzyme changes, rarely liver injury. Mild rises in liver markers and, rarely, clinically apparent liver injury have been noted; a consideration for anyone with existing liver concerns.
• Research-chemical supply has no quality control. Material sold as PT-141 outside the pharmaceutical system is unverified for identity, purity, and concentration. Unregulated melanocortin peptides have been found in forensic testing, and case reports of self-injected related peptides describe serious harm. Unverified supply adds risk on top of the compound's own pharmacology.
• MC4R is also expressed in appetite circuits. At the high dosing frequency used in some Phase 1 protocols, reduced food intake and body weight were observed — a pharmacological off-target effect to be aware of, not an approved or recommended use.

Where it fits in reproductive research

PT-141 (bremelanotide) occupies a distinctive position on this desk: it is the only compound here with a completed, successful Phase 3 program and an approved indication ^[10]. Its evidence for improving sexual desire in premenopausal women with HSDD is the strongest on this site — two large randomized trials, a long-term safety extension, and neuroimaging mechanistic data ^[9][10][11]. The limits are equally clear: the approval is narrow (premenopausal women with acquired, generalized HSDD only), the side-effect burden (especially nausea) is real, and use in men or for performance enhancement is extrapolated from mechanism, not from controlled evidence.

Compared to kisspeptin, which works upstream on the hormone axis and is still investigational across all indications, PT-141 represents what happens when central sexual neuropharmacology advances through a full development program. Together they show two different levers — hormonal and neural — for the same broad territory of reproductive and sexual health. See the comparison page for the side-by-side.